Fibrolamellar carcinoma (FLC) is a rare liver cancer that mostly affects young people and currently has no standard, effective treatment. Over the last decade, many studies have been conducted that have analyzed multiple types of biological data from the same cells or tissue to get a more complete picture of how the disease works, but they haven’t clearly examined how different cells inside the tumor interact with each other.
In this study, instead of studying the tumor as a whole, the team used advanced techniques that let them look at individual cells and their DNA activity. “Single‑cell” analysis is a way of studying a tumor by looking at results for each individual cell type instead of averaging everything together. This allows scientists to view the different kinds of cells present (like cancer, immune, and support cells), understand what each one is doing, and track how they communicate with each other. Specifically, the team performed single-cell RNA sequencing (which shows what genes each cell is using) and single-cell ATAC sequencing (which shows how the DNA is organized and regulated).
This approach let them:
- Identify different cell types inside the tumor
- Map how those cells communicate with each other
- Find key regulatory networks controlling the cancer.
Key findings:
- FLC tumors are made of many distinct cell types. They are a mix of cancer cells, immune cells, and structural/support cells. Each cell type behaves differently and plays its own role in the disease.
- Cell communication is “rewired” in FLC. The study found that cells in FLC talk to each other in unusual ways compared to normal tissue.They identified several important signaling pathways (ways in which cells send messages) that may help the tumor grow, survive, and resist treatment. These include:
- SPP1–CD44
- MIF–ACKR3
- GDF15–TGFBR2
- FGF7–FGFR.
- Specific genetic control systems are altered in FLC. They discovered:
- Unique gene activity patterns
- Changes in transcription factors (proteins that control gene expression)
- Special regulatory regions (“super-enhancers”) driving cancer behavior.
- Potential new treatment targets exist. Using lab models of the cancer and patient tumor samples, the researchers tested what happens when they block certain genes or pathways (called “loss-of-function” experiments). They identified weak points (vulnerabilities) in the cancer that could potentially be targeted by drugs.
Implications of the effort:
Importantly, this study shows that fibrolamellar carcinoma is driven not just by cancer cells themselves, but by a network of interacting cell types with abnormal communication pathways.
- It gives a much clearer picture of how this rare cancer works at the cellular level
- It maps out how FLC tumor cells and surrounding cells cooperate
- It points to new possible drug targets, which is crucial since no standard therapy exists.
The full pre-print of this article can be accessed here.
Note: This study was funded by a grant from FCF